I have an active basic and clinical research program. I have been principal investigator on several funded clinical studies including investigations of an oral ganciclovir prodrug to treat CMV retinitis and a study to determine the safety of a cyclosporine sustained drug delivery implant in the treatment of uveitis. I am principal investigator of an ongoing multicenter trial of a fluocinolone sustained drug delivery implant to treat patients with severe uveitis and a trial of this same implant to treat diabetic macular edema. Recently, I have investigated the use of ultrasonography and optical coherence tomography to diagnose macular edema in a variety of ocular diseases. I have maintained an ongoing basic research program to test the hypothesis that cytokines are important in the development of proliferative vitreoretinopathy, an important intraocular wound healing disorder. Education: I am actively involved in resident and fellow education. I give lectures to residents and fellows on a variety of topics related to uveitis and vitreoretinal diseases and train fellows to perform vitreoretinal surgery. I train post-doctoral students and medical students to conduct clinically relevant research. I serve as a mentor for the Duke third year medical school research program. I have served on a yearly basis as course faculty at many national and international meetings.
Education and Training
- University of California, San Francisco, School of Medicine, M.D. 1983
Selected Grants and Awards
- Novartis DRC Retinitis Pigmentosa
- Gemini DRC NH01 Genetic Screening and Registry GA with Dry AMD
- Gemini DRC NH02 Prospective Natural History
- Rate of Progression in EYS-Related Retinal Degeneration (PRO-EYS)
- Rate of Progression in USH2A Related Retinal Degeneration (RUSH2A)
- Diabetic Retinopathy Clinical Research Network (DRCR.net)
- Genentech DRC Phase 3 RPDS EXT (GR40549)
- IONIS DRC CS5 study GA secondary to AMD
- LMRI DRC Phase 3 Clinical Trial of CNTF for MacTel Type 2-NTMT-03
- Genentech DRC Phase 3 RPDS study (GR40548)
- Genentech DRC Phase 3 nAMD (LUCERNE) - GR40844
- Genentech DRC Phase 3 nAMD (TENAYA) - GR40306
- Astellas DRC Ph 1b/2 - Safety of ASP7317 for Atrophy Secondary to AMD
- Thrombogenics DRC Phase 1 THR-149 DME study
- Thrombogenics DRC Phase 1 THR-687 DME study
- Lumithera DRC Dry AMD LIGHTSITE III
- Eyevensys DRC Uveitis CT-2 ELECTRO study
- Santen DRC AVANTE Study (Phase II)
- LMRI DRC MacTel Phase II
- Regeneron DRC nAMD-1905 study
- Senju DRC Phase 2 AMD study (MT-0814)
- QLT DRC Phase 3 Inherited Retinal Disease (RET IRD 04)
- A CONTROLLED, MULTI-CENTER STUDY OF THE UTILIZATION AND SAFETY OF THE MK II INSERTER AND THE SAFETY OF THE FAI INSERT IN SUBJECTS WITH NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
- ONL DRC Phase 1 Retinal Detachment study
- Regenxbio DRC Phase 1 Gene Therapy nAMD study
- Roche DRC Phase 1 nAMD
- Kato DRC MEX-103 Diabetic Retinopathy
- Mallinckrodt DRC Uveitis Study
- DRC Editas Natural History Study of CEP290-Related Retinal Degeneration
- B&L 440 CORNEAL ENDOTHELIAL CELL DENSITY STUDY
- Novartis DRC Phase 3a nAMD study
- Corneal Endothelial Cell Density in Eyes Treated with a Flucinolone Acetonide Intravitreal Implant
- Quark DRC QRK207 (NAION)
- Evaluation of retinal cavitations in macular telangiectasia type 2 and response to ciliary neutrophic factor (CNTF)
- Eyevensys DRC Safety and Efficacy Uveitis study
- DRC- Roche Phase I study - Advanced BRAFV600 wild-type melanoma
- UPENN - Additional Analysis of Data from CATT and CATT Follow-up Studies
- Macular Edema Treatment Trials Associated with MUST (META-MUST)
- Envisia DRC ENV515
- Allgenesis DRC Pterygium Study
- DRC Allegro Dry AMD Study
- Ophthotech DRC Phase 2 OPH2007 nAMD study
- pSivida PSV-FAI-001 Duke as Site
- SciFluor DRC Wet AMD study
- DRC- OTX Ph 1 Safety Study in OAG or OHT Subjects Scheduled for Cataract Surgery
- PRN/Stealth DRC SPIAM-101
- Computer Aided Classification of Diabetic Macular Edema
- Regeneron DRC Phase 2 AMD study (R910-3-AMD-1517)
- Regeneron DRC Phase 2 DME Study (R910-3-DME-1518)
- Acucela DRC Phase 2a Macular Atrophy Secondary to Stargardt Disease
- Cleave Biosciences DRC Phase 1 Lymphoid Hematological Malicnancy (CLC-102)
- ThromboGenics DRC OASIS study - provide raw images
- BMS DRC Safety of BMS-936559 in Severe Sepsis
- UPenn - NEI Follow-up Study: Comparison of AMD Treatment Trials (CATT) YR3
- Neurotech DRC NT-503 (GEN 3)
- OCATA DRC AMD STUDY Phase II
- Multicenter Uveitis Steroid Treatment (MUST) Trial
- XOMA DRC Behcet's Trial X052133
- River Vision DRC DME
- Alcon DRC OVID II RTH255-P001
- Novartis DRC nAMD Phase 3 - 2201 study
- Novartis DRC nAMD Phase 3 - 2304 study
- Coordinating Center for the Comparison of AMD Treatments Trials
- Comparison of AMD Treatment Trials-OCT Reading Center
- Comparison of Age Related Macular DegenerationTreatment (CATT) OCT Reading Center
- Cytokine Modulation in Proliferative Vitreoretinopathy
- Cytokine Modulation In Proleferative Vitreoretinopathy
- Cytokine Modulation In Proliferative Vitreoretinopathy
- Cytokine Modulation In Proliferative Vtreoretinopathy
- Modulation Of Na+K+ Atpase In Retinal Detachment